ABVC BioPharma Inc
ABVC BioPharma Inc (ABVC) Historical Volatility
ABVC's 30 day historical volatility is 55.45%, in the 11th percentile of readings over the past year. This is a low percentile, meaning ABVC BioPharma Inc shares have been calmer than usual. ABVC's 30 day implied volatility sits at 337.34%, with an IV Rank of 46.83%, leaving IV 281.89 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking ABVC historical volatility helps you see how much ABVC BioPharma Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ABVC's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ABVC 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ABVC's 30 day historical volatility, or ABVC HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ABVC's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
Historical Volatility
Historical movement is subdued versus the past year. The stock has been unusually quiet.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →